LARIMAR THERAPEUTICS, INC. Net Cash Provided by (Used in) Operating Activities, Continuing Operations
LARIMAR THERAPEUTICS, INC. (LRMR) reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of -$13.27 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2018-05-10
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2018-03-31 was -$13.27M.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-12-31 was -$9.84M.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-09-30 was -$12.09M.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-06-30 was -$10.18M.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) operating activities, continuing operations for fiscal 2017 was -$43.78M.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) operating activities, continuing operations for fiscal 2016 was -$51.98M.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) operating activities, continuing operations for fiscal 2015 was -$59.55M.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) operating activities, continuing operations for fiscal 2014 was -$28.24M.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-03-31 | -$13.27M 10-Q · filed 2018-05-10 | -$23.10M derived: sum of 2 quarters · filed 2018-05-10 | -$35.19M derived: sum of 3 quarters · filed 2018-05-10 | -$45.37M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-12-31 | -$9.84M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | -$21.92M derived: sum of 2 quarters · filed 2018-03-09 | -$32.10M derived: sum of 3 quarters · filed 2018-03-09 | -$43.78M 10-K · filed 2018-03-09 |
| 2017-09-30 | -$12.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$22.27M derived: sum of 2 quarters · filed 2017-11-07 | -$33.95M 10-Q · filed 2017-11-07 | -$42.61M derived: sum of 4 quarters · filed 2018-03-09 |
| 2017-06-30 | -$10.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$21.86M 10-Q · filed 2017-08-09 | -$30.53M derived: sum of 3 quarters · filed 2018-03-09 | -$41.56M derived: sum of 4 quarters · filed 2018-03-09 |
| 2017-03-31 | -$11.68M 10-Q · filed 2018-05-10 | -$20.34M derived: sum of 2 quarters · filed 2018-03-09 | -$31.38M derived: sum of 3 quarters · filed 2018-03-09 | -$45.89M derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-12-31 | -$8.67M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | -$19.70M derived: sum of 2 quarters · filed 2018-03-09 | -$34.21M derived: sum of 3 quarters · filed 2018-03-09 | -$51.98M 10-K · filed 2018-03-09 |
| 2016-09-30 | -$11.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$25.55M derived: sum of 2 quarters · filed 2017-11-07 | -$43.31M 10-Q · filed 2017-11-07 | -$61.25M derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-06-30 | -$14.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$32.28M 10-Q · filed 2017-08-09 | -$50.22M derived: sum of 3 quarters · filed 2018-03-09 | -$66.36M derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-03-31 | -$17.76M 10-Q · filed 2017-05-09 | -$35.70M derived: sum of 2 quarters · filed 2018-03-09 | -$51.84M derived: sum of 3 quarters · filed 2018-03-09 | -$66.23M derived: sum of 4 quarters · filed 2018-03-09 |
| 2015-12-31 | -$17.94M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | -$34.08M derived: sum of 2 quarters · filed 2018-03-09 | -$48.47M derived: sum of 3 quarters · filed 2018-03-09 | -$59.55M 10-K · filed 2018-03-09 |
| 2015-09-30 | -$16.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$30.52M derived: sum of 2 quarters · filed 2016-11-09 | -$41.61M 10-Q · filed 2016-11-09 | -$53.32M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-06-30 | -$14.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | -$25.47M 10-Q · filed 2016-08-05 | -$37.19M derived: sum of 3 quarters · filed 2017-03-10 | -$43.47M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-03-31 | -$11.09M 10-Q · filed 2016-05-10 | -$22.80M derived: sum of 2 quarters · filed 2017-03-10 | -$29.08M derived: sum of 3 quarters · filed 2017-03-10 | -$35.31M derived: sum of 4 quarters · filed 2017-03-10 |
| 2014-12-31 | -$11.71M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | -$17.99M derived: sum of 2 quarters · filed 2017-03-10 | -$24.22M derived: sum of 3 quarters · filed 2017-03-10 | -$28.24M 10-K · filed 2017-03-10 |
| 2014-09-30 | -$6.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | -$12.51M derived: sum of 2 quarters · filed 2015-11-13 | -$16.53M 10-Q · filed 2015-11-13 | -$20.66M derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-06-30 | -$6.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | -$10.25M 10-Q · filed 2015-08-14 | -$14.38M derived: sum of 3 quarters · filed 2016-03-15 | -$17.82M derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-03-31 | -$4.02M 10-Q · filed 2015-05-14 | -$8.15M derived: sum of 2 quarters · filed 2016-03-15 | -$11.60M derived: sum of 3 quarters · filed 2016-03-15 | |
| 2013-12-31 | -$4.13M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$7.58M derived: sum of 2 quarters · filed 2016-03-15 | -$15.00M 10-K · filed 2016-03-15 | |
| 2013-09-30 | -$3.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | -$10.87M 10-Q · filed 2014-11-13 | ||
| 2013-06-30 | -$7.43M 10-Q · filed 2014-08-14 | |||
| 2012-12-31 | -$13.59M 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |